Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Dermatology Precision Panel > Tuberous Sclerosis Precision Panel

Tuberous Sclerosis Precision Panel

Tuberous Sclerosis Complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems. One of the main features of this disorder is the presence of multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney and skin.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Tuberous Sclerosis Complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems. One of the main features of this disorder is the presence of multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney and skin. It is an autosomal dominant genetic disorder caused by mutations in genes TSC1, TSC2 or IFNG that in turn affect cellular differentiation, proliferation and migration early in development. The most characteristic feature of TSC is adenoma sebaceum, which appears in late childhood or early adolescence. There is an increased risk of malignancy and susceptibility to epilepsy.  

  • The Igenomix Tuberous Sclerosis Precision Panel can be used to make an accurate and directed diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

Indication

  • The Igenomix Tuberous Sclerosis Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: 
    • Hamartomas and benign neoplasms in brain and various tissues (cerebral cortex, retina, heart, kidney) 
    • Adenoma sebaceum (angiofibromas) 
    • Hypopigmented macules  
    • Shagreen patches 
    • Epilepsy 
    • Behavioral problems 
    • Psychosocial difficulties 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of multidisciplinary treatment in the form of medical care with immunosuppressant medication as well as antiepileptic medications to prevent seizures. Early and routine surveillance is needed for malignancy screening. Surgical care for seizures may be necessary.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 

Genes & Diseases

Methodology

References

See scientific referrals

Crino, P., Nathanson, K., & Henske, E. (2006). The Tuberous Sclerosis Complex. New England Journal Of Medicine, 355(13), 1345-1356. doi: 10.1056/nejmra055323 

Schwartz, R., Fernández, G., Kotulska, K., & Jóźwiak, S. (2007). Tuberous sclerosis complex: Advances in diagnosis, genetics, and management. Journal Of The American Academy Of Dermatology, 57(2), 189-202. doi: 10.1016/j.jaad.2007.05.004 

Curatolo, P., Bombardieri, R., & Jozwiak, S. (2008). Tuberous sclerosis. The Lancet, 372(9639), 657-668. doi: 10.1016/s0140-6736(08)61279-9 

DiMario, F., Sahin, M., & Ebrahimi-Fakhari, D. (2015). Tuberous Sclerosis Complex. Pediatric Clinics Of North America, 62(3), 633-648. doi: 10.1016/j.pcl.2015.03.005 

Randle S. C. (2017). Tuberous Sclerosis Complex: A Review. Pediatric annals, 46(4), e166–e171. https://doi.org/10.3928/19382359-20170320-01 

Portocarrero, L., Quental, K. N., Samorano, L. P., Oliveira, Z., & Rivitti-Machado, M. (2018). Tuberous sclerosis complex: review based on new diagnostic criteria. Anais brasileiros de dermatologia, 93(3), 323–331. https://doi.org/10.1590/abd1806-4841.20186972 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information